The effect of aldosterone antagonist in experimental nephropathy induced by cyclosporine A

Renal Failure

Volumn 30, Issue 4, 2008, Pages 439-442

  Silva, Felipe Machado ^a   Miorin, Luiz Antonio ^a,b   Sens, Yvoty Alves Dos Santos ^a  

^a Santa Casa de Sao Paulo School of Medicine   (Brazil)

^b Avenida Piassanguaba No 962 Planalto Paulista ^*  (Brazil)

Author keywords

Aldosterone; Cyclosporine; Nephrotoxicity; Rats; Renal function

Indexed keywords

CYCLOSPORIN A; SPIRONOLACTONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; GLOMERULUS FILTRATION; HISTOPATHOLOGY; KIDNEY DISEASE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT;

ALDOSTERONE ANTAGONISTS; ANIMALS; CREATININE; CYCLOSPORINE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GLOMERULAR FILTRATION RATE; KIDNEY; MALE; NEPHROTIC SYNDROME; PROBABILITY; PROTEINURIA; RANDOM ALLOCATION; RATS; RATS, WISTAR; REFERENCE VALUES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SPIRONOLACTONE; STATISTICS, NONPARAMETRIC;

EID: 45749107215     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220801947397     Document Type: Article

References (23)

1. Kopp JB, Klotman PE. Cellular and molecular mechanisms of cyclosporin nephrotoxicity. J Am Soc Nephrol. 1990; 1:162-179.
2. Pichler RH, Franchesini N, Young BA, et al. Pathogenesis of cyclosporine nephropathy: Roles of angiotensin II and osteopontin J Am Soc Nephrol. 1995;6:1186-1196.
3. Yang CW, Ahn HJ, Kim WY, et al. Influence of renin-angiotensin system on epidermal growth factor expression in normal and cyclosporin-treated rat kidney. Kidney Int. 2001;60:847-857.
4. Shihab FS, Andoh TF, Tanner AM et al. Role of transforming growth factor-beta-1 in experimental chronic cyclosporine nephropathy. Kidney Int. 1996;49:1141-1151.
5. Thomas SE, Andoh TF, Pichler RH, et al. Accelerated apoptosis characterizes cyclosporine-associated interstitial fibrosis. Kidney Int. 1998;53:897-908.
6. Amore A, Emancipator SN, Cirina P, et al. Nitric oxide mediates cyclosporine induced apoptosis in cultured renal cells. Kidney Int. 1997;52:660-673.
7. Shihab FS, Yi H, Bennett WM, Andoh TF. Effect of nitric oxide modulation on TGF-beta 1 and matrix proteins in chronic cyclosporine nephrotoxicity. Kidney Int. 2000;58:1174-1185.
8. Bobadilha NA, Gamba G, Tapia E, et al. Role of NO in cyclosporin nephrotoxicity: effects of chronic NO inhibition and NO synthases gene expression. Am J Physiol Renal Physiol. 1998;274:791-798.
9. Thomas SE, Andoh TF, Pichler RH, et al. Accelerated apoptosis characterizes cyclosporine associated interstitial fibrosis. Potential role of angioten II, nitric oxide and renal ischemia. Kidney Int. 1998;53:897-908.
10. Lassila M. Interaction of cyclosporine A and the rennin-angiotensin system: New perspectives. Curr Drug Metab. 2002;3:61-71.
11. Arima S, Kohagura K, Xu HL, et al. Nongenomic vascular action of aldosterone in the glomerular microcirculation. J Am Soc Nephrol. 2003;14:2255-2263.
12. Arima S. Aldosterone and the kidney: Rapid regulation of renal microcirculation. Steroids. 2006;71:281-285.
13. Virdis A, Neves MF, Amiri F, et al. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension. 2002;40:504-510.
14. Aldigier JC, Kanjanbuch T, Ma LJ, et al. Regression of existing glomerulosclerosis by inhibition of aldosterone. J Am Soc Nephrol. 2005;16:3306-3314.
15. Feria I, Pichardo I, Juarez P, et al. Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. Kidney Int. 2003;63:43-52.
16. Perez-Rojas JM, Derive S, Blanco JA, et al. Renocortical mRNA expression of vasoactive factors during spironolactone protective effect in chronic cyclosporine nephrotoxicity. Am J Physiol Renal Physiol. 2005;289:F1020-F1030.
17. Elzinga LW, Rosen S, Bennett WM. Dissociation of glomerular filtration rate from tubulointerstitial fibrosis in experimental chronic cyclosporine nephropathy: Role of sodium intake. J Am Soc Nephrol. 1993;4:214-221.
18. Young BA, Burdmann EA, Johson RJ, et al. Cellular proliferation and macrophage influx precede interstitial fibrosis in cyclosporine nephropathy. Kidney Int. 1995;48:439-448.
19. Iacona A, Rossetti A, Filinger V, et al. Reduced nephrotoxicity, and hepatoxicity in cyclosporin A therapy by enalapril and spironolactone in rats. Drugs Exp Clin Res. 1991;17:501-506.
20. Shihab FS, Bennet WM, Tanner AM, Andoh TF. Angiotensin II blockade decreases TGF beta-1 and matrix proteins in cyclosporine nephropathy. Kidney Int. 1997;52:660-673.
21. da Costa MC, de Castro I, Cuvello Neto AL, et al. Cyclosporin A tubular effects contribute to nephrotoxicity: role for Ca2+ and Mg2+ ions. Nephrol Dial Transplant. 2003;18:2262-2268.
22. Satyanarayana PS, Chopa K. Oxidative stress-mediated renal dysfunction by cyclosporine A in rats: Attenuation by trimetazidine. Ren Fail. 2002;24:259-274.
23. Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 2006;70(12):2051-2053.